Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access
Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc
Journal website https://www.cardiologyres.org

Original Article

Volume 9, Number 3, June 2018, pages 137-143

Extended Duration Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Peripheral Arterial Disease: A Meta-Analysis

Figures

Figure 1.
Figure 1. Summary of the study selection and exclusion process.
Figure 2.
Figure 2. MACCE associated with a short versus extended DAPT use in patients with PAD after PCI.
Figure 3.
Figure 3. GUSTO moderate/severe bleeding events associated with a short versus extended DAPT use in patients with PAD after PCI.
Figure 4.
Figure 4. Definite or probable stent thrombosis events associated with a short versus extended DAPT use in patients with PAD after PCI.
Figure 5.
Figure 5. MI events associated with a short versus extended DAPT use in patients with PAD after PCI.
Figure 6.
Figure 6. Cardiac death events associated with a short versus extended DAPT use in patients with PAD after PCI.
Figure 7.
Figure 7. All-cause death events associated with a short versus extended DAPT use in patients with PAD after PCI.
Figure 8.
Figure 8. Risk of bias graph for the studies included in this systematic review. Green +: yes (low risk of bias); yellow ?: unclear; red -: no (high risk of bias).

Tables

Table 1. Summary of the DAPT Trial and PRODIGY Trial
 
The PRODIGY trialThe DAPT trial
CABG: coronary artery bypass grafting; MI: myocardial infarction; PAD: peripheral artery disease; SD: standard deviation.
No of patients197011,648
No of patients with PAD246649
Randomization groupsAspirin 75 - 160 mg/d + clopidogrel 75 mg/d vs. aspirin + placeboAspirin 75 - 162 mg/d + clopidogrel 75 mg/d or prasugrel 10/5 mg/d vs. aspirin + placebo
Follow-up≤ 6-month vs. 24-month12-month vs. 30-month
Age among patients with PAD (SD)74.5 (8.94)66.2 (9.57)
Male among patients with PAD76.83%70.42%
Diabetes mellitus among patients with PAD33.74%44.29%
Hypertension among patients with PAD87.40%87.98%
Smoking among patients with PAD15.45%28.55%
Congestive heart failure among patients with PAD6.50%14.73%
Prior PCI among patients with PAD23.98%40.87%
Prior CABG among patients with PAD17.89%25.15%
Prior MI among patients with PAD40.65%30.77%
Indication for PCI
  STEMI among patients with PAD20.32%4.62%
  NSTE-ACS among patients with PAD52.44%26.81%
  Stable angina among patients with PAD27.23%44.53%

 

Table 2. Effect of PAD on Clinical Outcomes in the DAPT Trial and PRODIGY Trial
 
DAPT trialPRODIGY trial
% Patients with PAD (n = 649)% Patients without PAD (n = 10,999)P value% Patients with PAD (n = 246)% Patients without PAD (n = 1,724)P value
ST: stent thrombosis; MACCE: major adverse cardiovascular and cerebrovascular event; MI: myocardial infarction.
MACCE11.65 (73)4.62 (494)< 0.00121.9 (54)8.4 (144)< 0.001
MI5.88 (36)2.90 (308)< 0.0017.5 (18)3.6 (62)0.006
Definite/probable ST1.47 (9)0.83 (88)0.0943.0 (7)1.2 (21)0.04
GUSTO moderate/severe bleeding4.86 (30)1.74 (185)< 0.0012.6 (6)2.7 (45)0.95